Samaneh Kamali is a scientific entrepreneur with over 14 years of experience developing patient-derived preclinical models across inflammation, fibrosis, and oncology. She is the founder of Caleo Biotechnologies, a company focused on bridging the gap between traditional preclinical testing and real patient biology.
Her work centers on the development of Organ-Dish (OD), a proprietary platform for drug development that recreates patient-specific tissue architecture and disease phenotypes in a self-organizing, multicellular system. The OD platform enables high-fidelity mechanistic studies, drug screening, toxicology assessment, and preclinical validation in both fibrotic diseases and cancer.
Samaneh has led translational research programs in both academia and industry, secured early-stage funding, and evaluated biotech innovations from both scientific and commercial perspectives—all with a focus on making precision medicine more predictive and actionable.
At Caleo Biotechnologies, she is advancing next-generation, patient-first technologies by combining biological complexity with computational imaging to create scalable systems for understanding disease progression and therapeutic response at the individual patient level.
